Apologic, Inc.

Cincinnati, OH 45219

SBIR Award Summary

Total Number of Awards 4
Total Value of Awards $850K
First Award Date 08/01/98
Most Recent Award Date 02/15/02

Key Personnel

Last Name Name Awards Contact
Marques Marcos A Marques 4

4 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/15/02 - 07/31/03

The strategy proposed here for developing novel therapies for treating Alzheimer's disease is based on the finding that neurotoxic and amyloid-depositing fragments apolipoprotein E may play a role in this disease. This, in turn, suggests that degradation of this protein contributes to the pathological changes that occur. If so, a novel approac...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/01 - 03/31/02

There are four million people with Alzheimer's disease (AD) in the U.S. alone and the cost of their care is currently estimated at 100 billion dollars. Available therapy is limited to symptomatic relief without affecting the underlying cause of the disease. Recent evidence indicates that apolipoprotein E (apoE) may play a direct role in neuropat...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/00 - 03/31/01

There are four million people with Alzheimer's disease (AD) in the U.S. alone and the cost of their care is currently estimated at 100 billion dollars. Available therapy is limited to symptomatic relief without affecting the underlying cause of the disease. Recent evidence indicates that apolipoprotein E (apoE) may play a direct role in neuropat...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/98 - 01/31/99

Ther are two to four million people with Alzheimer's disease (AD) in the U.S. alone and the cost of their care is currently estimated at 100 billion dollars. Current therapy is limited to symptomatic relief. The number of patients in which the disease is predicted by a single gene is relatively low (5-10...